Zentalis Pharmaceuticals Inc (ZNTL)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.21-8.30%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Zentalis Pharmaceuticals Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.505
Annual ending 2026-12-31
Revenue	—	2.14M
EPS	—	-2.06
Annual ending 2027-12-31
Revenue	—	9.35M
EPS	—	-1.898

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance ASPENOVA Phase 3 trial for azenosertib	It is advancing the ASPENOVA Phase 3 trial for azenosertib.	Improving	Trial progress stalls or is delayed significantly in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The first patient was dosed in the ASPENOVA Phase 3 trial in 2026-Q1, with enrollment ongoing to support full approval. The trial is designed to enroll about 420 patients. Management continues to emphasize this confirmatory trial as a key step toward regulatory approval, showing active advancement. Delivery assessment Oct 24, 2026
Optimize azenosertib dosing in DENALI trial	The company chose the best dose for azenosertib in DENALI.	Intact	Dose optimization is reversed or questioned in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Complete DENALI Part 2 enrollment by year-end 2026	Zentalis aims to finish DENALI Part 2 enrollment by end of 2026.	Intact	Enrollment not completed by end of 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management expects to complete enrollment in all DENALI Part 2 cohorts and provide a topline readout by year-end 2026 or 1H 2027. Cash decreased from $211.8M in 2026-Q1 to $174.6M in 2026-Q2, with operating expenses rising from $37.9M to $44.4M, reflecting ongoing trial costs. The trajectory shows continued focus and progress toward enrollment completion and data readout. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.90

$-1.63 → $-1.90 · observed estimates

FY2027 revenue$0.01B

$0.02B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.63	$22,111,458	7 / 7
2026-07-25	$-1.53	$19,275,220	8 / 10
2026-07-26	$-1.53	$19,275,220	8 / 10
2026-07-27	$-1.53	$19,275,220	8 / 10
2026-07-28	$-1.63	$22,111,458	7 / 7
2026-07-29	$-1.53	$19,275,220	8 / 10
2026-07-30	$-1.53	$19,275,220	8 / 10
2026-07-31	$-1.53	$19,275,220	8 / 10
2026-08-01	$-1.63	$22,111,458	7 / 7
2026-08-02	$-1.53	$19,275,220	8 / 10
2026-08-03	$-1.53	$19,275,220	8 / 10
2026-08-04	$-1.53	$19,275,220	8 / 10
2026-08-05	$-1.53	$19,275,220	8 / 10
2026-08-06	$-1.63	$22,111,458	7 / 7
2026-08-08	$-1.63	$22,111,458	7 / 7
2026-08-09	$-1.63	$22,111,458	7 / 7
2026-08-10	$-1.53	$19,275,220	8 / 10
2026-08-12	$-1.79	$16,378,020	8 / 10
2026-08-13	$-1.63	$22,111,458	7 / 7
2026-08-14	$-1.63	$22,111,458	7 / 7
2026-08-15	$-1.63	$22,111,458	7 / 7
2026-08-16	$-1.63	$22,111,458	7 / 7
2026-08-17	$-1.63	$22,111,458	7 / 7
2026-08-18	$-1.63	$22,111,458	7 / 7
2026-08-19	$-1.63	$22,111,458	7 / 7
2026-08-20	$-2.01	$8,944,111	7 / 7
2026-08-21	$-2.01	$8,944,111	7 / 7
2026-08-22	$-2.01	$8,944,111	7 / 7
2026-08-23	$-2.01	$8,944,111	7 / 7
2026-08-24	$-2.01	$8,944,111	7 / 7
2026-08-25	$-2.01	$8,944,111	7 / 7
2026-08-26	$-2.01	$8,944,111	7 / 7
2026-08-27	$-2.01	$8,944,111	7 / 7
2026-08-28	$-2.01	$8,944,111	7 / 7
2026-08-29	$-1.98	$11,856,551	7 / 7
2026-08-30	$-1.98	$11,856,551	7 / 7
2026-08-31	$-1.98	$11,856,551	7 / 7
2026-09-01	$-1.98	$11,856,551	7 / 7
2026-09-02	$-1.98	$11,856,551	7 / 7
2026-09-03	$-1.98	$11,856,551	7 / 7
2026-09-04	$-1.98	$11,856,551	7 / 7
2026-09-05	$-1.98	$11,856,551	7 / 7
2026-09-06	$-1.98	$11,856,551	7 / 7
2026-09-07	$-1.98	$11,856,551	7 / 7
2026-09-08	$-1.98	$11,856,551	7 / 7
2026-09-09	$-1.98	$11,856,551	7 / 7
2026-09-10	$-1.98	$11,856,551	7 / 7
2026-09-11	$-1.98	$11,856,551	7 / 7
2026-09-12	$-1.98	$11,856,551	7 / 7
2026-09-13	$-1.98	$11,856,551	7 / 7
2026-09-14	$-1.98	$11,856,551	7 / 7
2026-09-15	$-1.98	$11,856,551	7 / 7
2026-09-16	$-1.95	$11,856,551	7 / 7
2026-09-17	$-1.95	$10,778,683	8 / 7
2026-09-18	$-1.95	$10,778,683	8 / 7
2026-09-19	$-1.95	$10,778,683	8 / 7
2026-09-20	$-1.95	$10,778,683	8 / 8
2026-09-21	$-1.95	$10,778,683	8 / 8
2026-09-22	$-1.95	$10,778,683	8 / 8
2026-09-23	$-1.95	$10,778,683	8 / 8
2026-09-24	$-1.95	$10,778,683	8 / 8
2026-09-25	$-1.95	$10,778,683	8 / 8
2026-09-26	$-1.95	$10,778,683	8 / 8
2026-09-27	$-1.95	$10,778,683	8 / 8
2026-09-28	$-1.95	$10,778,683	8 / 8
2026-09-29	$-1.95	$10,778,683	8 / 8
2026-09-30	$-1.95	$10,778,683	8 / 8
2026-10-01	$-1.95	$10,778,683	8 / 8
2026-10-02	$-1.95	$10,778,683	8 / 7
2026-10-03	$-1.95	$10,778,683	8 / 7
2026-10-04	$-1.95	$10,778,683	8 / 7
2026-10-05	$-1.95	$10,778,683	8 / 7
2026-10-06	$-1.93	$9,351,410	8 / 7
2026-10-07	$-1.93	$9,351,410	8 / 7
2026-10-08	$-1.93	$9,351,410	8 / 7
2026-10-09	$-1.93	$9,351,410	8 / 7
2026-10-10	$-1.93	$9,351,410	8 / 7
2026-10-11	$-1.93	$9,351,410	8 / 7
2026-10-12	$-1.93	$9,351,410	8 / 7
2026-10-13	$-1.93	$9,351,410	8 / 7
2026-10-14	$-1.93	$9,351,410	8 / 7
2026-10-15	$-1.90	$9,351,410	8 / 7
2026-10-16	$-1.90	$9,351,410	8 / 7
2026-10-17	$-1.90	$9,351,410	8 / 7
2026-10-18	$-1.90	$9,351,410	8 / 7
2026-10-19	$-1.90	$9,351,410	8 / 7
2026-10-20	$-1.90	$9,351,410	8 / 7
2026-10-21	$-1.90	$9,351,410	8 / 7
2026-10-22	$-1.90	$9,351,410	8 / 7
2026-10-23	$-1.90	$9,351,410	8 / 7
2026-10-24	$-1.90	$9,351,410	8 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	4	5
2026-06-01	4	5
2026-07-01	5	5
2026-08-01	5	5
2026-09-01	6	5
2026-10-01	8	5

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Leerink PartnersOct 5

$8.00New observation · no comparable prior

$0$4.40$8.80

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Advance ASPENOVA Phase 3 trial for azenosertibDirect metric needs a verified mapping
Optimize azenosertib dosing in DENALI trialDirect metric needs a verified mapping
Complete DENALI Part 2 enrollment by year-end 2026Direct metric needs a verified mapping

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.3%Typical daily move · historical

Downside history

-67.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Zentalis Pharmaceuticals Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage biotechnology, not a business with established earnings: it is loss-making and carries high risk. The long-term thesis is on watch, with management advancing key trials but recent financial performance well below its industry cohort.

What's priced into Zentalis Pharmaceuticals Inc

The valuation evidence points to ZNTL being cheap versus peers, but confidence in that comparison is low. The snapshot gives little direct evidence about what investors expect from future trial results, so the expectations gap is unclear.

What the fundamentals likely do

Near term, earnings-miss risk is elevated, and an August 2026 earnings miss adds to the weak recent record. Cash fell from $211.8 million in the first quarter of 2026 to $174.6 million in the second, while operating expenses rose, as trial costs continued. Over the multi-year view, progress depends on completing DENALI Part 2 and advancing the ASPENOVA confirmatory trial; management has kept these priorities in focus, but their status remains mixed.

What Zentalis Pharmaceuticals Inc hinges on

A favorable path depends on completing DENALI Part 2 enrollment and delivering its topline readout by year-end 2026 or the first half of 2027, while continuing ASPENOVA and combination trials. Near-term downside risks include a guidance cut and weaker employment data, while strength in major healthcare peers could support sector momentum. These factors do not resolve the central uncertainty: whether trial progress can support a durable business.